Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Return to: PBR Home | Drug Research
Today in Drug Research

Drug Research

Eisai and Halozyme to evaluate combination drug for treatment of metastatic breast cancer Eisai and Halozyme Therapeutics have agreed to evaluate the combination of their drugs, Halaven (eribulin) and PEGPH20 (PEGylated recombinant human hyaluronidase), respectively, in the treatment of first line HER2-negative metastatic breast cancer. Drug Research > Drug Discovery & Development > News

Latest Drug Research News by Sector

Select a sector from the list or browse by sector below:

Drug Delivery

Novavax reports positive Phase II trial results of quadrivalent seasonal influenza VLP vaccine
By PBR Staff Writer
US-based Novavax has reported positive top-line data from a Phase II clinical trial of its recombinant quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate (Seasonal Influenza VLP).
Drug Research > Drug Delivery > News
FDA approves deltoid injection site for abilify maintena for extended-release injectable suspension to treat schizophrenia
Otsuka America Pharmaceutical and Lundbeck announced that the US Food and Drug Administration (FDA) has expanded the label of Abilify Maintena (aripiprazole) for extended-release injectable suspension to include a new injection site, the deltoid muscle of the arm.
Drug Research > Drug Delivery > News

Drug Discovery & Development

Japan's MHLW approves patient enrollment in ADRESU trial for stress urinary incontinence
By PBR Staff Writer
US-based Cytori Therapeutics has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval to start patient enrollment in a company-supported ADRESU trial.
Drug Research > Drug Discovery & Development > News
Merck reports positive data from Phase III ring vaccination trial of Ebola vaccine rVSV-ZEBOV
Merck (known as MSD outside the US and Canada) said that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100% efficacy in an analysis of interim data from a Phase III ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet.
Drug Research > Drug Discovery & Development > News